PharmaCielo Announces Revocation of FFCTO and Related Corporate Matters

Core Viewpoint - PharmaCielo Ltd. has successfully revoked the failure to file cease trade order (FFCTO) and is set to resume trading on the TSX Venture Exchange after filing its required financial documents [2][3]. Financial Performance - For the six months ended September 30, 2025, PharmaCielo reported revenue of $1,212,000, a decrease from $2,113,000 in the same period of 2024 [4]. - The company recorded an adjusted EBITDA loss of $531,000, improving from a loss of $2,218,000 year-over-year [4]. - The net loss for the period was $2,687,000, down from $5,219,000 in the previous year, with a net loss per share of $0.014 compared to $0.031 [4]. Corporate Developments - The Ontario Securities Commission has revoked the FFCTO issued on August 5, 2025, allowing the company to move forward with its operations [2]. - The company has strengthened its balance sheet and streamlined operations in Colombia, aligning commercial efforts with the growing demand for high-quality cannabis products [3]. Debt and Financing - PharmaCielo has an aggregate principal balance of $2,150,000 in secured bridge loans from related parties, with an interest rate of 11% per annum [5]. - The company has issued 985 debenture units for total gross proceeds of $985,000, maturing on June 30, 2026, with each unit consisting of an 11% secured debenture and non-transferable common share purchase warrants [8]. Working Capital and Liabilities - As of September 30, 2025, PharmaCielo reported a working capital deficiency of $20,026,086, but has maintained adequate resources to support operations [10]. - Current liabilities include accounts payable and accrued liabilities of $5.73 million, current debt of $2.39 million, and current debentures of $15.43 million [13]. Future Outlook - The company aims to build consistent export volumes, deepen international partnerships, and selectively expand into profitable markets [3].